Literature DB >> 6313897

Ligand selectivity of dog coronary adenosine receptor resembles that of adenylate cyclase stimulatory (Ra) receptors.

S Kusachi, R D Thompson, R A Olsson.   

Abstract

Adenosine receptors on the surface of coronary myocytes initiate coronary relaxation, but events subsequent to receptor occupancy are uncertain. We assayed the coronary vasoactivity of receptor-selective adenosine analogs in open chest dogs to test the hypothesis that the coronary adenosine receptor is an adenylate cyclase stimulatory (Ra) receptor. The potency order was: ethyl adenosine-5'-uronamide greater than cyclopropyl adenosine-5'-uronamide greater than 2-chloroadenosine greater than N6-[R(-)-1-phenyl-2-propyl] adenosine (R-PIA) greater than N6-cyclohexyladenosine greater than adenosine greater than S-PIA. Such a hierarchy of activity resembles that of the Ra receptors of thyroid and aortic myocyte adenylate cyclases and of tracheal smooth muscle relaxation. The potency order R-PIA greater than adenosine and the stereoselective coronary vasoactivity of R-PIA suggest that the coronary receptor may be a hybrid receptor which contains the "N6 site" typical of inhibitory (Ri) receptors in addition to the "5'-uronamide site' which expresses Ra activity.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6313897

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  23 in total

1.  Functional evidence for the presence of adenosine A2-receptors in cultured coronary endothelial cells.

Authors:  C Des Rosiers; S Nees
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-07       Impact factor: 3.000

2.  Characterization of the adenosine receptor in porcine coronary arteries.

Authors:  A D King; M Milavec-Krizman; E Müller-Schweinitzer
Journal:  Br J Pharmacol       Date:  1990-07       Impact factor: 8.739

3.  Evidence that A2 purinoceptors are involved in endothelium-dependent relaxation of the rat thoracic aorta.

Authors:  R B Rose'Meyer; W Hope
Journal:  Br J Pharmacol       Date:  1990-07       Impact factor: 8.739

4.  Inhibition of platelet aggregation by adenosine receptor agonists.

Authors:  G Cristalli; S Vittori; R D Thompson; W L Padgett; D Shi; J W Daly; R A Olsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-06       Impact factor: 3.000

5.  Deoxyribose analogues of N6-cyclopentyladenosine (CPA): partial agonists at the adenosine A1 receptor in vivo.

Authors:  R A Mathôt; E M Van der Wenden; W Soudijn; A P IJzerman; M Danhof
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

6.  Covalent binding of a selective agonist irreversibly activates guinea pig coronary artery A2 adenosine receptors.

Authors:  K Niiya; K A Jacobson; S K Silvia; R A Olsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-05       Impact factor: 3.000

7.  A1- and A2-selective adenosine antagonists: in vivo characterization of cardiovascular effects.

Authors:  G Evoniuk; K A Jacobson; M T Shamim; J W Daly; R J Wurtman
Journal:  J Pharmacol Exp Ther       Date:  1987-09       Impact factor: 4.030

8.  Relaxation by adenosine and its analogs of potassium-contracted human coronary arteries.

Authors:  M H Sabouni; M V Ramagopal; S J Mustafa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-04       Impact factor: 3.000

9.  Vascular actions of purines in the foetal circulation of the human placenta.

Authors:  M A Read; A L Boura; W A Walters
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

10.  Functional characterization of three adenosine receptor types.

Authors:  M F Gurden; J Coates; F Ellis; B Evans; M Foster; E Hornby; I Kennedy; D P Martin; P Strong; C J Vardey
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.